Hot topics in antibody-drug conjugate development

被引:0
|
作者
Thudium, Karen [1 ]
Bilic, Sanela [1 ]
机构
[1] Novartis Pharmaceut, Clin Pharmacol, Oncol Business Unit, E Hanover, NJ 07936 USA
关键词
BIOANALYTICAL METHOD VALIDATION; MACROMOLECULES;
D O I
10.4155/BIO.13.276
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
American Association of Pharmaceutical Scientists National Biotechnology Conference Sheraton San Diego Hotel and Marina, San Diego, CA, USA, 19-23 May 2013 The National Biotechnology Conference, is a premier meeting for biotechnology professionals covering a broad range of hot topics in the biotechnology industry. Attracting participants from academia, industry and regulatory, this meeting features sessions that aim to address emerging subjects of interest and allows for open exchange between scientists. The 2013 conference featured leading researchers in the fields of antibody-drug conjugates (ADCs) and immunogenicity. Herein, we present a summary of the ADC hot topics, including bioanalytical and PK considerations, quantitative evaluation of the impact of immunogenicity and ADME to understand ADC drug-drug interactions, and clinical considerations for ADC development. This article aims to summarize the recommendations that were made by the speakers during various sessions throughout the conference.
引用
收藏
页码:2989 / 2993
页数:5
相关论文
共 50 条
  • [1] Antibody-drug conjugate drug development: where are the challenges?
    Wright, Laura
    Baughman, Sharon
    Wake, Ashleigh
    BIOANALYSIS, 2013, 5 (12) : 1467 - 1469
  • [2] Stepping forward in antibody-drug conjugate development
    Jin, Yiming
    Schladetsch, Megan A.
    Huang, Xueting
    Balunas, Marcy J.
    Wiemer, Andrew J.
    PHARMACOLOGY & THERAPEUTICS, 2022, 229
  • [3] Development of an antibody-drug conjugate with broad anticancer activity
    Lin, Siang-Yo
    Szekely, Zoltan
    Lin, Chen-Yong
    Bertino, Joseph R.
    Rather, Gulam Mohmad
    CANCER RESEARCH, 2017, 77
  • [4] Antibody-Drug Conjugate Targets
    Teicher, B. A.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (08) : 982 - 1004
  • [5] An Immunosuppressive Antibody-Drug Conjugate
    Wang, Rongsheng E.
    Liu, Tao
    Wang, Ying
    Cao, Yu
    Du, Jintang
    Luo, Xiaozhou
    Deshmukh, Vishal
    Kim, Chan Hyuk
    Lawson, Brian R.
    Tremblay, Matthew S.
    Young, Travis S.
    Kazane, Stephanie A.
    Wang, Feng
    Schultz, Peter G.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (09) : 3229 - 3232
  • [6] The antibody-drug conjugate landscape
    Flynn, Patrick
    Suryaprakash, Smruthi
    Grossman, Dan
    Panier, Val
    Wu, John
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (08) : 577 - 578
  • [7] Bioprocess development of antibody-drug conjugate production for cancer treatment
    Ou, Jianfa
    Si, Yingnan
    Goh, KahYong
    Yasui, Norio
    Guo, Yichen
    Song, Jiajia
    Wang, Lizhong
    Jaskula-Sztul, Renata
    Fan, Jinda
    Zhou, Lufang
    Liu, Runhua
    Liu, Xiaoguang
    PLOS ONE, 2018, 13 (10):
  • [8] Kinetic reaction modeling for antibody-drug conjugate process development
    Andris, Sebastian
    Seidel, Jonathan
    Hubbuch, Juergen
    JOURNAL OF BIOTECHNOLOGY, 2019, 306 : 71 - 80
  • [9] Development of a novel antibody-drug conjugate for refractory lymphoid malignancies
    Arita, Daigo
    Saijho, Sinji
    Matsumura, Yasuhiro
    Yasunaga, Masahiro
    CANCER SCIENCE, 2018, 109 : 389 - 389
  • [10] Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
    Kaur, Surinder
    Xu, Keyang
    Saad, Ola M.
    Dere, Randall C.
    Carrasco-Triguero, Montserrat
    BIOANALYSIS, 2013, 5 (02) : 201 - 226